JP2019026583A5 - - Google Patents

Download PDF

Info

Publication number
JP2019026583A5
JP2019026583A5 JP2017146374A JP2017146374A JP2019026583A5 JP 2019026583 A5 JP2019026583 A5 JP 2019026583A5 JP 2017146374 A JP2017146374 A JP 2017146374A JP 2017146374 A JP2017146374 A JP 2017146374A JP 2019026583 A5 JP2019026583 A5 JP 2019026583A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017146374A
Other languages
English (en)
Japanese (ja)
Other versions
JP6945377B2 (ja
JP2019026583A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2017146374A priority Critical patent/JP6945377B2/ja
Priority claimed from JP2017146374A external-priority patent/JP6945377B2/ja
Publication of JP2019026583A publication Critical patent/JP2019026583A/ja
Publication of JP2019026583A5 publication Critical patent/JP2019026583A5/ja
Application granted granted Critical
Publication of JP6945377B2 publication Critical patent/JP6945377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017146374A 2017-07-28 2017-07-28 エルロチニブを有効成分とする医薬錠剤及びその製造方法 Active JP6945377B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2017146374A JP6945377B2 (ja) 2017-07-28 2017-07-28 エルロチニブを有効成分とする医薬錠剤及びその製造方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2017146374A JP6945377B2 (ja) 2017-07-28 2017-07-28 エルロチニブを有効成分とする医薬錠剤及びその製造方法

Publications (3)

Publication Number Publication Date
JP2019026583A JP2019026583A (ja) 2019-02-21
JP2019026583A5 true JP2019026583A5 (enExample) 2020-05-21
JP6945377B2 JP6945377B2 (ja) 2021-10-06

Family

ID=65475681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017146374A Active JP6945377B2 (ja) 2017-07-28 2017-07-28 エルロチニブを有効成分とする医薬錠剤及びその製造方法

Country Status (1)

Country Link
JP (1) JP6945377B2 (enExample)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2801349A1 (en) * 2013-05-06 2014-11-12 Siegfried AG Oral Pharmaceutical Formulation
US20150065526A1 (en) * 2013-09-05 2015-03-05 Emory University Overcoming acquired resistance to chemotherapy treatments through suppression of stat3

Similar Documents

Publication Publication Date Title
JP2017107167A5 (enExample)
JP2014179090A5 (enExample)
JP2017142496A5 (enExample)
JP2019523723A5 (enExample)
JP2019124943A5 (enExample)
JP2018054415A5 (enExample)
JP2017528346A5 (enExample)
JP2021503553A5 (enExample)
JP2017179103A5 (enExample)
JP2016069397A5 (enExample)
JP2018144050A5 (enExample)
JP2017203885A5 (enExample)
JP2019526558A5 (enExample)
JP2018538325A5 (enExample)
JP2017020017A5 (enExample)
JP2016157119A5 (enExample)
JP2018513162A5 (enExample)
JP2016074795A5 (enExample)
JP2015174850A5 (enExample)
JP2019106905A5 (enExample)
JP2016077539A5 (enExample)
JP2018195967A5 (enExample)
JP2019026656A5 (enExample)
JP2017145384A5 (enExample)
JP2017114849A5 (enExample)